fbpx

David B. Rawlins, PhD
drawlins@roseman.edu
Interim Assistant Dean for Research
College of Pharmacy
(702) 968-1684

Dr. David Rawlins is a medicinal chemist who worked in drug discovery within the pharmaceutical industry prior to coming to Roseman University. He earned a Bachelor of Science in Microbiology with a minor in Chemistry and a Master of Science in Organic Chemistry at Brigham Young University, followed by a Doctor of Philosophy in Organic Chemistry at Stanford University. He serves as the Interim Assistant Dean for Research and as an Assistant Professor of Pharmaceutical Sciences at Roseman University of Health Sciences. He teaches courses in Molecular Biology, Biotechnology, Pharmacogenomics, Medicinal Chemistry, Pharmacognosy, and Pharmaceutical Calculations.

Dr. Rawlins has served as principal and co-principal investigator on multiple research projects involving topical ophthalmic drugs, evaluations of essential oils, and substance abuse in school age children. He has authored and co-authored numerous publications focused on antidepressants, glycemic control in mice, and the treatment of diabetes and has been awarded 17 patents. He is a member of the American Chemical Society, American Association of Colleges of Pharmacy, and the American Association of Pharmaceutical Scientists.

Prior to joining Roseman University of Health Sciences, Dr. Rawlins was the Executive Director of Medicinal Chemistry and Cheminformatics at Lexicon Pharmaceuticals. He currently serves as a pharmaceutical consultant to several companies.

  • American Chemical Society
  • American Association of Colleges of Pharmacy
  • American Association of Pharmaceutical Scientists
  • Topical Ophthalmic Drugs
  • Evaluations of Essential Oils
  • Substance Abuse in School Age Children

Riccio, KK; Rawlins, DB; Talbot, JN; Boyd, CJ; Demonstration of smartphones as viable tools for adolescent substance use surveillance: completion rate and response comparisons across electronic modes. Substance Use and Misuse, published online 12 Dec 2019, DOI: 10.1080/10826084.2019.1696822.

Yellepeddi, VK; Zhudeva, MY; Movahedi, F; Vo, A; Phan, J; Kirsh, RD; Rawlins, DB; Talbot, JN; Biopharmaceutical characterization and oral efficacy of a new rapid acting antidepressant Ro 25-6981; J. Pharm. Sci., 2018, published online May 17, 2018.

Talbot, JN; Rawlins, DB; Movahedi, F; Zhudeva, MY; Vo, A; Phan, J; Dorigatti, J; Velazquez, G; Kirsh RD; Yellepeddi, VK; The in vivo pharmacodynamic and biopharmaceutical characterization of a novel dual mechanism, rapid-acting antidepressant; The FASEB Journal, 2017, 31, Supplement 663.6.

Powell, DR; Smith, MG; Doree, DD; Harris, AL; Greer, J; DaCosta, CM; Thompson, A; Liu, J; Jeter-Jones, S; Carson, K; Goodwin, NC; Harrison, BA; Rawlins, DB; Strobel, E; Gopinathan, S; Wilson, A; Mseeh, F; Sands, AT; Zambrowicz, B; Ding, Z-M; LX2761, an SGLT1 inhibitor restricted to the intestine, improves glycemic control in mice; J. Pharm. Exp. Ther., 2017, 362, 85-97.

Goodwin, NC; Ding, Z-M; Harrison, BA; Strobel, E; Harris, A; Smith, M; Thompson, A; Xiong, W; Mseeh, F; Bruce, D; Diaz, D; Gopinathan, S; Li, L; O’Neill, E; Thiel, M; Wilson, A; Carson, K; Powell, D; Rawlins, DB; Discovery of LX2761, an SGLT1 inhibitor restricted to the intestinal lumen, for the treatment of diabetes; J. Med. Chem. 2017, 60, 710-721.

Goodwin, NC.; Cianchetta, G; Burgoon, HA; Healy, J; Mabon, R; Strobel, ED; Allen, J; Wang, S; Hamman, BD; Rawlins, DB; Discovery of a type III inhibitor of LIM kinase 2 that binds in a DFG-out conformation; Med. Chem. Lett. 2015, 6, 53-57.

Harrison, BA; Almstead, ZY; Burgoon, H; Gardyan, M; Goodwin, NC; Healy, J; Liu, Y; Mabon, R; Marinelli, B; Samala, L; Zhang, Y; Stouch, T; Whitlock, NA; Hamman, BD; Gopinathan, S; McKnight, B; Crist, M; Wang, S; Patel, N; Wilson, AGE; Rice, DS; Rawlins, DB; The discovery and development of LX7101, a LIM-kinase 2 inhibitor for the treatment of glaucoma; Med. Chem. Lett. 2015, 6, 84–88.

  • 2019 - Active Printed Films as Ocular Delivery Devices Designed to Increase the Residency Time of Topical Ophthalmic Drugs Roseman University of Health Sciences - Principle Investigator
  • 2018 - Active Evaluation of Essential Oils; dōTERRA Inc. - Co-investigator.
  • 2017-2018 Validation and implementation of the Secondary Student Life Survey: Nevada (SSLS:NV). Digipath Labs – Co-investigator